Review
Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis
Eficacia y seguridad clínica del ixekizumab para el tratamiento de la psoriasis
Leído
9688
Vecesse ha leído el artículo
3217
Total PDF
6471
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 109 | 8 | 117 |
| 2025 5 | 177 | 43 | 220 |
| 2025 4 | 180 | 40 | 220 |
| 2025 3 | 162 | 42 | 204 |
| 2025 2 | 197 | 53 | 250 |
| 2025 1 | 115 | 39 | 154 |
| 2024 12 | 105 | 40 | 145 |
| 2024 11 | 96 | 62 | 158 |
| 2024 10 | 75 | 47 | 122 |
| 2024 9 | 80 | 37 | 117 |
| 2024 8 | 109 | 68 | 177 |
| 2024 7 | 92 | 55 | 147 |
| 2024 6 | 106 | 73 | 179 |
| 2024 5 | 103 | 48 | 151 |
| 2024 4 | 98 | 32 | 130 |
| 2024 3 | 117 | 45 | 162 |
| 2024 2 | 106 | 32 | 138 |
| 2024 1 | 106 | 43 | 149 |
| 2023 12 | 113 | 31 | 144 |
| 2023 11 | 128 | 38 | 166 |
| 2023 10 | 134 | 30 | 164 |
| 2023 9 | 111 | 43 | 154 |
| 2023 8 | 116 | 23 | 139 |
| 2023 7 | 130 | 37 | 167 |
| 2023 6 | 92 | 38 | 130 |
| 2023 5 | 90 | 30 | 120 |
| 2023 4 | 71 | 28 | 99 |
| 2023 3 | 99 | 17 | 116 |
| 2023 2 | 73 | 38 | 111 |
| 2022 1 | 65 | 34 | 99 |
| 2022 12 | 127 | 36 | 163 |
| 2022 11 | 83 | 50 | 133 |
| 2022 10 | 127 | 39 | 166 |
| 2022 9 | 97 | 54 | 151 |
| 2022 8 | 105 | 53 | 158 |
| 2022 7 | 91 | 54 | 145 |
| 2022 6 | 64 | 32 | 96 |
| 2022 5 | 64 | 57 | 121 |
| 2022 4 | 126 | 56 | 182 |
| 2022 3 | 89 | 62 | 151 |
| 2022 2 | 69 | 31 | 100 |
| 2021 1 | 136 | 43 | 179 |
| 2021 12 | 111 | 69 | 180 |
| 2021 11 | 78 | 53 | 131 |
| 2021 10 | 45 | 70 | 115 |
| 2021 9 | 35 | 38 | 73 |
| 2021 8 | 42 | 48 | 90 |
| 2021 7 | 32 | 35 | 67 |
| 2021 6 | 36 | 34 | 70 |
| 2021 5 | 45 | 59 | 104 |
| 2021 4 | 87 | 84 | 171 |
| 2021 3 | 86 | 36 | 122 |
| 2021 2 | 65 | 33 | 98 |
| 2020 1 | 46 | 32 | 78 |
| 2020 12 | 43 | 24 | 67 |
| 2020 11 | 35 | 25 | 60 |
| 2020 10 | 30 | 30 | 60 |
| 2020 9 | 49 | 27 | 76 |
| 2020 8 | 35 | 34 | 69 |
| 2020 7 | 52 | 29 | 81 |
| 2020 6 | 46 | 41 | 87 |
| 2020 5 | 37 | 23 | 60 |
| 2020 4 | 32 | 29 | 61 |
| 2020 3 | 31 | 15 | 46 |
| 2020 2 | 7 | 2 | 9 |
| 2020 1 | 3 | 0 | 3 |
| 2019 12 | 4 | 0 | 4 |
| 2019 11 | 4 | 0 | 4 |
| 2019 9 | 4 | 0 | 4 |
| 2019 8 | 4 | 0 | 4 |
| 2019 7 | 4 | 0 | 4 |
| 2019 6 | 4 | 0 | 4 |
| 2019 5 | 4 | 1 | 5 |
| 2019 4 | 2 | 3 | 5 |
| 2019 3 | 1 | 2 | 3 |
| 2019 2 | 7 | 5 | 12 |
| 2019 1 | 6 | 0 | 6 |
| 2018 12 | 4 | 0 | 4 |
| 2018 11 | 3 | 0 | 3 |
| 2018 10 | 3 | 2 | 5 |
| 2018 9 | 3 | 3 | 6 |
| 2018 7 | 2 | 0 | 2 |
| 2018 5 | 1 | 0 | 1 |
| 2018 4 | 1 | 3 | 4 |
| 2018 3 | 0 | 4 | 4 |
| 2018 2 | 155 | 14 | 169 |
| 2018 1 | 151 | 16 | 167 |
| 2017 12 | 180 | 27 | 207 |
| 2017 11 | 76 | 24 | 100 |
| 2017 10 | 44 | 20 | 64 |
| 2017 9 | 20 | 17 | 37 |
| 2017 8 | 18 | 25 | 43 |
| 2017 7 | 16 | 20 | 36 |
| 2017 6 | 35 | 30 | 65 |
| 2017 5 | 63 | 74 | 137 |
| 2017 4 | 11 | 31 | 42 |
| 2017 3 | 0 | 50 | 50 |
| 2017 2 | 0 | 33 | 33 |
| 2016 1 | 0 | 55 | 55 |
| 2016 12 | 0 | 64 | 64 |
| 2016 11 | 0 | 63 | 63 |
Mostrar todo
